ArticleJournal of ovarian research2025
Mesenchymal stem cells derived extracellular vesicles ameliorate ovarian aging through inhibiting LGALS3BP/NF-κB induced inflammation.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Restoring glucose metabolic homeostasis to attenuate ovarian aging: mechanisms and clinical prospects.Journal of ovarian research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroudOvarian aging can lead to early menopause, infertility, and even premature senility in female patients, seriously impairing the quality of life. Unfortunatly, it is still lack of effective protection strategies against ovarian aging. It has been emergingly recognized that mesenchymal stem cells (MSCs) play a pivotal role in the maintenance of organ and tissue homeostasis and extracellular vesicles (EVs) have been identified as significant contributors to the paracrine action of MSCs. Human umbilical cord derived MSCs (UCMSCs) are distinguished by their superior self-renewal potential, minimal immunogenicity, and plentiful supply, rendering them an excellent candidate for EV-based therapeutic transplantation. However, whether UCMSC-EVs improve ovarian aging though regulating inflammation is still uncertain.
methodsIn this study, EVs derived from umbilical cord mesenchymal stem cells were isolated using ultracentrifugation. The protein markers and morphology of EVs were characterized. Their effect on human ovarian granulosa cells (GCs) and ovarian aging mice models were assessed using ROS assay, CCK-8 and AM/PI assay, HE staining, Masson staining, western blotting, RNA sequencing and bioinformatic analysis. The proteomic profiling of EVs was conducted via LC-MS/MS assay, with subsequent pathway analysis employing cell transfection and western blotting to evaluate the efficacy of UCMSC-EVs.
resultsOur research demonstrated that UCMSC-EVs markedly improved ovarian function, cellular apoptosis and inflammation of aging mice. Subsequently, our results further indicated that UCMSC-EVs facilitated the transport of LGALS3BP to injured ovarian granular cells, modulated NF-κB-mediated inflammatory pathway, and then mitigated ovarian senescence. Meanwhile, the absence of LGALS3BP in UCMSC-EVs impaired the amelioration of inflammatory and the functional improvement in ovarian senescence.
conclusionMSC-EVs derived anti-inflammation and pro-regeneration effect confirmed their therapeutic potential in amelioration of ovarian aging, and further revel the underlying mechanisms by modulating the NF-κB-mediated inflammatory pathways will promote their clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.